



## Arena Pharmaceuticals to Release First Quarter 2018 Financial Results and Provide Corporate Update on Tuesday, May 8

May 2, 2018

SAN DIEGO, May 2, 2018 /PRNewswire/ -- [Arena Pharmaceuticals, Inc.](#) (NASDAQ: ARNA) today announced that the Company will release its first quarter 2018 financial results and provide a corporate update on Tuesday, May 8, 2018, after the close of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community the same day at 4:30 p.m. EDT.

### Conference Call & Webcast Information

When: May 8, 2018, 4:30 p.m. EDT

Dial-in: (877) 643-7155 (United States) or (914) 495-8552 (International)

Conference ID: 7698222

Please join the conference call at least 10 minutes early to register. You can access the live webcast under the investor relations section of Arena's website at: [www.arenapharm.com](http://www.arenapharm.com). A replay of the conference call will be archived under the [investor relations](#) section of Arena's website for 30 days after the call.

### About Arena Pharmaceuticals

[Arena Pharmaceuticals](#) is focused on developing novel, small molecule drugs with optimized receptor pharmacology and pharmacokinetics designed to deliver broad clinical utility across several therapeutic areas. Arena's proprietary pipeline includes potentially first- or best-in-class programs. The most advanced investigational clinical programs are [ralinepag](#) (APD811), which will be commencing a Phase 3 program for pulmonary arterial hypertension (PAH), and [etrasimod](#) (APD334), which will be commencing a Phase 3 program for ulcerative colitis (UC) and which has potential utility for a broad range of immune and inflammatory conditions. Arena is also evaluating [APD371](#) in Phase 2 for the treatment of pain associated with Crohn's disease. In addition, Arena has collaborations with the following pharmaceutical companies: Everest Medicines Limited (ralinepag and etrasimod in Greater China and select Asian countries), Boehringer Ingelheim International GmbH (undisclosed target - preclinical), Outpost Medicine, LLC (undisclosed target – preclinical), Axovant Sciences GmbH (nelotanserin - Phase 2), and Eisai Co., Ltd. and Eisai Inc. (BELVIQ® - marketed product).

### Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's focus, and the potential of its programs and collaborations. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

### Corporate Contact:

Kevin R. Lind

Arena Pharmaceuticals, Inc.

Executive Vice President and

Chief Financial Officer

[klind@arenapharm.com](mailto:klind@arenapharm.com)

858.210.3636

### Media Contact:

Matt Middleman, M.D.

LifeSci Public Relations

[matt.middleman@lifescipublicrelations.com](mailto:matt.middleman@lifescipublicrelations.com)

646.627.8384



[results-and-provide-corporate-update-on-tuesday-may-8-300640699.html](#)

SOURCE Arena Pharmaceuticals, Inc.